TRCT
WHWK

Tower Research Capital (TRC)’s Whitehawk Therapeutics WHWK Stock Holding History

Tower Research Capital (TRC)’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-797
Closed -$1.51K – 5750
2025
Q3 		$1.51K Sell
797
-3,301
-81% -$6.07K ﹤0.01% 4774
2025
Q2 		$7.66K Buy
4,098
+1,543
+60% +$2.69K ﹤0.01% 4044
2025
Q1 		$4.55K Buy
2,555
+2,141
+517% +$5.59K ﹤0.01% 4240
2024
Q4 		$1.31K Sell
414
-1,379
-77% -$3.12K ﹤0.01% 5049
2024
Q3 		$3.69K Sell
1,793
-11,875
-87% -$19.2K ﹤0.01% 4795
2024
Q2 		$20K Buy
13,668
+10,169
+291% +$18.8K ﹤0.01% 3766
2024
Q1 		$8.19K Sell
3,499
-1,772
-34% -$3.42K ﹤0.01% 4065
2023
Q4 		$10.6K Sell
5,271
-11,330
-68% -$47.5K ﹤0.01% 4220
2023
Q3 		$80.3K Buy
16,601
+15,081
+992% +$87.7K ﹤0.01% 2148
2023
Q2 		$10.4K Buy
1,520
+392
+35% +$3.05K ﹤0.01% 4127
2023
Q1 		$8K Sell
1,128
-3,488
-76% -$37.3K ﹤0.01% 4683
2022
Q4 		$60K Sell
4,616
-1,846
-29% -$24.1K ﹤0.01% 2214
2022
Q3 		$91K Buy
6,462
+2,408
+59% +$31.6K ﹤0.01% 2648
2022
Q2 		$50K Buy
4,054
+2,607
+180% +$38.7K ﹤0.01% 2887
2022
Q1 		$25K Buy
1,447
+1,277
+751% +$24.5K ﹤0.01% 3341
2021
Q4 		$4K Buy
170
+130
+325% +$3.27K ﹤0.01% 5355
2021
Q3 		$1K Buy
+40
New +$1.22K ﹤0.01% 5557
2021
Q2 		– Sell
-219
Closed -$4K – 5919
2021
Q1 		$4K Sell
219
-8
-4% -$184 ﹤0.01% 4819
2020
Q4 		$3K Buy
227
+46
+25% +$984 ﹤0.01% 4837
2020
Q3 		$4K Sell
181
-833
-82% -$17.5K ﹤0.01% 4449
2020
Q2 		$19K Buy
+1,014
New +$13.3K ﹤0.01% 3714
2019
Q1 		– Sell
-274
Closed -$7K – 4365
2018
Q4 		$7K Buy
+274
New +$8.72K ﹤0.01% 2727
2018
Q3 		– Sell
-7
Closed – – 4320
2018
Q2 		$0 Buy
+7
New +$423 ﹤0.01% 4135

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Tower Research Capital (TRC)'s WHWK Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Whitehawk Therapeutics (WHWK) in Q4 2025, closing a stake of 797 shares — an estimated $1.51K sold.

Tower Research Capital (TRC) first reported a position in WHWK in Q2 2018 and held it in 23 quarters. The position peaked at $91K in Q3 2022. 48 funds tracked by Wall St. Rank hold WHWK as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Whitehawk Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 797 Whitehawk Therapeutics shares in Q4 2025, an estimated $1.51K.
  • Tower Research Capital (TRC) first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 23 quarters.
  • Tower Research Capital (TRC)'s Whitehawk Therapeutics position peaked at $91K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.